Frontiers in Pharmacology,
Journal Year:
2022,
Volume and Issue:
13
Published: June 17, 2022
Rehmanniae
Radix
(RR,
the
dried
tuberous
roots
of
Rehmannia
glutinosa
(Gaertn.)
DC.)
is
an
important
traditional
Chinese
medicine
distributed
in
Henan,
Hebei,
Inner
Mongolia,
and
Northeast
China.
RR
frequently
used
to
treat
diabetes
mellitus,
cardiovascular
disease,
osteoporosis
aging-related
diseases
a
class
prescriptions.
The
oligosaccharides
catalpol
have
been
confirmed
neuroprotective
effects.
However,
there
are
few
studies
on
anti-Alzheimer’s
disease
(AD)
effect
(ORR).
chemical
components
pharmacological
effects
(DRR)
prepared
(PRR)
different
because
processing
methods.
ORR
has
potential,
such
as
improving
learning
memory
rats.
Therefore,
this
study
aimed
prove
importance
DRR
(ODRR)
PRR
(OPRR)
for
AD
based
Caenorhabditis
elegans
(
C.
)
model
roles
ODRR
OPRR
treatment
AD.
In
study,
we
paralysis
assays,
lifespan
stress
resistance
bacterial
growth
curve,
developmental
behavioral
parameters,
ability
explore
anti-AD
anti-aging.
Furthermore,
accumulation
reactive
oxygen
species
(ROS);
deposition
Aβ;
expression
amy-1,
sir-2.1,
daf-16,
sod-3,
skn-1,
hsp-16.2
were
analyzed
confirm
efficacy
OPRR.
was
more
effective
than
delaying
paralysis,
ability,
prolonging
.
Further
mechanism
showed
that
ROS,
aggregation,
toxicity
Aβ
reduced,
suggesting
alleviated
Aβ-induced
toxicity,
part,
through
antioxidant
activity
aggregation
inhibiting.
amy-1
downregulated,
upregulated.
Thus,
could
possible
therapeutic
by
modulating
hsp-16.2.
promoted
nuclear
localization
daf-16
further
increased
sod-3
hsp-16.2,
which
significantly
contributed
inhibiting
enhancing
oxidative
resistance.
summary,
provided
new
idea
development
ORR.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Aug. 23, 2024
Abstract
Alzheimer’s
disease
(AD)
stands
as
the
predominant
form
of
dementia,
presenting
significant
and
escalating
global
challenges.
Its
etiology
is
intricate
diverse,
stemming
from
a
combination
factors
such
aging,
genetics,
environment.
Our
current
understanding
AD
pathologies
involves
various
hypotheses,
cholinergic,
amyloid,
tau
protein,
inflammatory,
oxidative
stress,
metal
ion,
glutamate
excitotoxicity,
microbiota-gut-brain
axis,
abnormal
autophagy.
Nonetheless,
unraveling
interplay
among
these
pathological
aspects
pinpointing
primary
initiators
require
further
elucidation
validation.
In
past
decades,
most
clinical
drugs
have
been
discontinued
due
to
limited
effectiveness
or
adverse
effects.
Presently,
available
primarily
offer
symptomatic
relief
often
accompanied
by
undesirable
side
However,
recent
approvals
aducanumab
(
1
)
lecanemab
2
Food
Drug
Administration
(FDA)
present
potential
in
disrease-modifying
Nevertheless,
long-term
efficacy
safety
need
Consequently,
quest
for
safer
more
effective
persists
formidable
pressing
task.
This
review
discusses
pathogenesis,
advances
diagnostic
biomarkers,
latest
updates
trials,
emerging
technologies
drug
development.
We
highlight
progress
discovery
selective
inhibitors,
dual-target
allosteric
modulators,
covalent
proteolysis-targeting
chimeras
(PROTACs),
protein-protein
interaction
(PPI)
modulators.
goal
provide
insights
into
prospective
development
application
novel
drugs.
Brain,
Journal Year:
2022,
Volume and Issue:
145(7), P. 2250 - 2275
Published: March 12, 2022
Currently,
enhancement
of
cholinergic
neurotransmission
via
cholinesterase
inhibitors
represents
the
main
available
approach
to
treat
cognitive
and
behavioural
symptoms
early
as
well
late
stages
Alzheimer's
disease.
Restoring
system
has
been
a
primary
means
improving
cognition
in
disease,
four
six
approved
therapies
are
acetylcholinesterase
inhibitors.
Memantine
is
an
N-methyl-d-aspartate
antagonist
with
well-documented
clinical
effect
on
symptoms,
which
often
added
potentiate
their
aducanumab,
targeting
amyloid
pathology,
recently
approved.
The
early,
progressive
selective
degeneration
together
its
close
relation
deficits
supports
use
therapy
for
This
review
provides
updated
view
basal
forebrain
system,
relevance
It
deals
three
aspects
that
form
basis
cholinergic-oriented
origin,
mechanism
action,
effects,
advantages
limits
therapeutic
approach.
includes
new
overview
involvement
muscarinic
receptors
disease
recent
development
highly
M1
receptor
agonists
disease-modifying
potential.
also
addresses
discovery
novel
nerve
growth
factor
metabolic
pathway
responsible
trophic
maintenance
deregulation
discusses
studies
evidence
long-term
efficacy
inhibitor
suggesting
these
drugs.
classical
symptomatic
based
judiciously
discussed
maximal
best
application.
proposes
alternatives
should
be
developed
amplify
supplement
treatments
slow
down
or
arrest
progression.
Acta Pharmaceutica Sinica B,
Journal Year:
2023,
Volume and Issue:
13(10), P. 3988 - 4024
Published: July 16, 2023
In
recent
years,
growing
awareness
of
the
role
oxidative
stress
in
brain
health
has
prompted
antioxidants,
especially
dietary
to
receive
attention
as
possible
treatments
strategies
for
patients
with
neurodegenerative
diseases
(NDs).
The
most
widely
studied
antioxidants
include
active
substances
such
vitamins,
carotenoids,
flavonoids
and
polyphenols.
Dietary
are
found
usually
consumed
foods
fresh
fruits,
vegetables,
nuts
oils
gaining
popularity
due
recently
their
potential
preventive
protective
agents
against
NDs,
well
abundant
natural
sources,
generally
non-toxic
nature,
ease
long-term
consumption.
This
review
article
examines
development
explores
‘two-sidedness’
blood–brain
barrier
(BBB)
a
nervous
system
an
impeding
use
drug
medicinal
products
and/or
supplements
prevention
therapy
reviews
BBB
permeability
common
suplements
efficacy
treatment
NDs.
Finally,
current
challenges
future
directions
NDs
using
discussed,
useful
information
on
is
provided.
Cells,
Journal Year:
2024,
Volume and Issue:
13(6), P. 511 - 511
Published: March 14, 2024
Neuroinflammatory
and
neurodegenerative
disorders
including
Alzheimer’s
disease
(AD),
Parkinson’s
(PD),
traumatic
brain
injury
(TBI)
Amyotrophic
lateral
sclerosis
(ALS)
are
chronic
major
health
disorders.
The
exact
mechanism
of
the
neuroimmune
dysfunctions
these
pathogeneses
is
currently
not
clearly
understood.
These
show
dysregulated
inflammatory
responses,
activation
neurons,
glial
cells,
neurovascular
unit
damage
associated
with
excessive
release
proinflammatory
cytokines,
chemokines,
neurotoxic
mediators,
infiltration
peripheral
immune
cells
into
brain,
as
well
entry
mediators
through
damaged
endothelial
blood–brain
barrier
tight
junction
proteins.
Activation
leads
to
many
molecules
that
cause
neuroinflammation
neurodegeneration.
Gulf
War
Illness
(GWI)
myalgic
encephalomyelitis/chronic
fatigue
syndrome
(ME/CFS)
also
dysfunctions.
Currently,
there
no
effective
disease-modifying
therapeutic
options
available
for
diseases.
Human
induced
pluripotent
stem
cell
(iPSC)-derived
astrocytes,
microglia,
pericytes
used
models
drug
discovery.
This
review
highlights
certain
recent
trends
in
neuroinflammatory
responses
iPSC-derived
applications
Life,
Journal Year:
2021,
Volume and Issue:
11(1), P. 28 - 28
Published: Jan. 6, 2021
Although
the
mechanisms
of
toxic
activity
tau
are
not
fully
recognized,
it
is
supposed
that
toxicity
related
rather
to
insoluble
aggregates
but
its
intermediate
forms.
It
seems
neurofibrillar
tangles
(NFTs)
themselves,
despite
being
composed
tau,
probably
neither
necessary
nor
sufficient
for
tau-induced
neuronal
dysfunction
and
toxicity.
Tau
oligomers
(TauOs)
formed
during
early
stages
aggregation
pathological
forms
play
a
key
role
in
eliciting
loss
neurons
behavioral
impairments
several
neurodegenerative
disorders
called
tauopathies.
They
can
be
found
tauopathic
diseases,
most
common
which
Alzheimer’s
disease
(AD).
Evidence
co-occurrence
b-amyloid,
α-synuclein,
into
their
forms,
i.e.,
oligomers,
suggests
these
species
interact
influence
each
other’s
The
mechanism
responsible
oligomeric
neurotoxicity
subject
intensive
investigation.
In
this
review,
we
summarize
recent
literature
on
damaging
effect
TauOs
stability
genome
function
nucleus,
energy
production
mitochondrial
function,
cell
signaling
synaptic
plasticity,
microtubule
assembly,
cytoskeleton
axonal
transport,
effectiveness
protein
degradation
system.
Cells,
Journal Year:
2021,
Volume and Issue:
10(4), P. 779 - 779
Published: April 1, 2021
Alzheimer’s
disease
(AD),
a
progressive
neurodegenerative
disorder
characterized
by
memory
loss
and
cognitive
decline,
is
major
cause
of
death
disability
among
the
older
population.
Despite
decades
scientific
research,
underlying
etiological
triggers
are
unknown.
Recent
studies
suggested
that
gut
microbiota
can
influence
AD
progression;
however,
potential
mechanisms
linking
with
pathogenesis
remain
obscure.
In
present
study,
we
provided
mechanistic
link
between
dysbiotic
neuroinflammation
associated
progression.
Using
mouse
model
AD,
discovered
unfavorable
correlated
abnormally
elevated
expression
NLRP3
lead
to
peripheral
inflammasome
activation,
which
in
turn
exacerbates
AD-associated
neuroinflammation.
To
this
end,
observe
significantly
altered
compositions
young
old
5xFAD
mice
compared
age-matched
non-transgenic
mice.
Moreover,
demonstrated
compromised
barrier
function
as
evident
from
tight
junction
adherens
proteins
Concurrently,
observed
increased
IL-1β
production
gut.
Consistent
our
hypothesis,
gut–microbial–inflammasome
activation
positively
enhanced
astrogliosis
microglial
along
higher
brains
These
data
indicate
components
may
be
an
important
trigger
for
subsequent
downstream
inflammatory
potentially
cytotoxic
mediators,
gastrointestinal
promote
inflammasome-mediated
Thus,
modulation
strategy
treatment
AD-related
neurological
disorders
genetically
susceptible
hosts.
International Journal of Molecular Sciences,
Journal Year:
2021,
Volume and Issue:
22(7), P. 3612 - 3612
Published: March 31, 2021
Alzheimer’s
disease
(AD)
is
a
growing
concern
in
modern
society,
and
effective
drugs
for
its
treatment
are
lacking.
Uncaria
rhynchophylla
(UR)
main
alkaloids
have
been
studied
to
treat
neurodegenerative
diseases
such
as
AD.
This
study
aimed
uncover
the
key
components
mechanism
of
anti-AD
effect
UR
through
network
pharmacology
approach.
The
analysis
identified
10
from
based
on
HPLC
that
corresponded
90
targets.
A
potential
alkaloid
target-AD
target
indicated
corynoxine,
corynantheine,
isorhynchophylline,
dihydrocorynatheine,
isocorynoxeine
likely
become
AD
treatment.
KEGG
pathway
enrichment
revealed
Alzheimers
(hsa05010)
was
most
significantly
enriched
against
Further
28
out
targets
were
correlated
with
Aβ
tau
pathology.
These
validated
using
Gene
Expression
Omnibus
(GEO)
dataset.
Molecular
docking
studies
carried
verify
binding
corynoxine
corynantheine
core
related
In
addition,
cholinergic
synapse
(hsa04725)
dopaminergic
(hsa04728)
pathways
enriched.
Our
findings
indicate
directly
exert
an
by
acting
multiple
pathological
processes